Responses
Regular Abstracts – Part 2
Clinical Trial Completed
629-C Phase 2 safety and efficacy of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with non-small cell lung cancer not previously treated with checkpoint inhibitor
Compose a Response to This Article
Other responses
No responses have been published for this article.